Evidence map›Paper›PMID 32952615›Full record

ReviewTherapeutic advances in urology

Immunotherapy in prostate cancer: current state and future perspectives.

Shivani Handa, Bandhul Hans, Shokhi Goel, Hafis O Bashorun, Zach Dovey, Ashutosh Tewari

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic advances in urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. What do cancer-specific T cells 'see'?Discovery immunology · 2023
    Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shivani HandaDepartment of Internal Medicine, Icahn School of Medicine, Mount Sinai Morningside and West Hospital, New York, NY, 10019, USA.ORCID https://orcid.org/0000-0002-1932-6209
Bandhul HansDepartment of Internal Medicine, Allegheny General Hospital, Pittsburgh, PA, USA.ORCID https://orcid.org/0000-0003-3006-0672
Shokhi GoelDepartment of Urology, Icahn School of Medicine, Mount Sinai Hospital, New York, NY, USA.
Hafis O BashorunDepartment of Urology, Icahn School of Medicine, Mount Sinai Hospital, New York, NY, USA.
Zach DoveyDepartment of Urology, Icahn School of Medicine, Mount Sinai Hospital, New York, NY, USA.
Ashutosh TewariDepartment of Urology, Icahn School of Medicine, Mount Sinai Hospital, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic castrate resistant prostate cancer (PCa) remains an incurable entity. In the era of immunotherapy, the complex PCa microenvironment poses a unique challenge to the successful application of this class of agents. However, in the last decade, a tremendous effort has been made to explore this field of therapeutics. In this review, the physiology of the cancer immunity cycle is highlighted in the context of the prostate tumor microenvironment, and the current evidence for use of various classes of immunotherapy agents including vaccines (dendritic cell based, viral vector based and DNA/mRNA based), immune checkpoint inhibitors, Chimeric antigen receptor T cell therapy, antibody-mediated radioimmunotherapy, antibody drug conjugates, and bispecific antibodies, is consolidated. Finally, the future directions for combinatorial approaches to combat PCa are discussed.

Indexed as

adoptive cell therapycancer-immunity cyclecancer vaccinesCAR-T cellimmune checkpoint inhibitorimmunotherapymetastatic castration resistant prostate cancerProstate cancerradioimmunotherapySipuleucel-T

Identifiers

PMID32952615
PMCPMC7476347

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.